Abzena PLC Business update on US and UK facilities
January 05 2018 - 2:00AM
RNS Non-Regulatory
TIDMABZA
Abzena PLC
05 January 2018
Abzena plc
Abzena takes on new facilities in Cambridge, UK and San
Diego
Cambridge, UK 5 January 2018 - Abzena plc (AIM: ABZA, 'Abzena'
or the 'Group'), the life sciences group providing services and
technologies to enable the development and manufacture of
biopharmaceutical products, provides an update on its UK and US
facilities.
In Cambridge, UK, the Group's lease has commenced for 30,000
square feet of space in Building 900 on the Babraham Research
Campus, as first announced in February 2015. This building has been
developed by Imperial College ThinkSpace ("Imperial") under a
long-lease granted to Imperial for land owned by BBSRC. The
building is being managed by Babraham Bioscience Technologies Ltd
("BBT"), the company that develops and manages the Babraham
Research Campus. Abzena is consolidating all its UK operations
including the head office functions, biology and chemistry research
services groups from its two current buildings on the campus into
this new facility during January 2018.
The new building has been purpose-built to accommodate Abzena's
needs and enables all the Group's UK-based science teams to work
together in a single, state-of-the-art facility.
The Group has also entered into an agreement with BBT to run and
develop the antibody discovery services formerly provided by BBT's
Technology Development Laboratory.
As previously communicated in the interim results announcement
of 12 December 2017, Abzena has negotiated and now concluded a
lease for a 50,000 square feet facility at Lusk Boulevard, San
Diego to consolidate the West Coast biomanufacturing operations
into a single state of the art facility. Abzena's process and
analytical development groups will relocate from the existing
Torrey Pines laboratories in the second quarter of this year.
Following further remodelling of the facility, enabled by
substantial landlord-funded tenant improvements to create the
biomanufacturing clean rooms to accommodate 500L and 2,000 litre
bioreactors, the manufacturing group will relocate to the new
facility. The facility is expected to be fully operational from
early 2019.
The Group has entered into a preferred biomanufacturing
equipment supply and services agreement, as announced by Sartorius
Stedim Biotech SA on 4 January 2018, to supply the bioprocess
reactor equipment, process analytic software and to provide support
for the design of the new biomanufacturing facility in San
Diego.
The creation of the GMP conjugation suite at Abzena's Bristol,
PA facility is continuing on track and is expected to be
operational around the end of the first quarter of 2018.
John Burt, CEO of Abzena, commented:
"The new facilities in Cambridge and San Diego are an important
strategic step in the delivery of our integrated services model and
will greatly enhance Abzena's operations. The combination of
state-of-the-art facilities and leading technologies will enable
the Group to support its international customers as they progress
their drug development programs from research into clinical
trials."
-Ends-
Enquiries:
Abzena plc
John Burt, Chief Executive
Officer Julian Smith, Chief
Financial Officer +44 1223 903498
Instinctif Partners +44 20 7457
Melanie Toyne Sewell / Alex 2020
Shaw / Deborah Bell abzena@instinctif.com
Notes to Editors
About Abzena
Abzena (AIM: ABZA) provides proprietary technologies and
complementary services to enable the development and manufacture of
biopharmaceutical products.
The term 'ABZENA Inside' is used by Abzena to describe products
that have been created using its proprietary technologies and are
being developed by its partners, and include Composite Human
Antibodies(TM) and ThioBridge(TM) Antibody Drug Conjugates (ADCs).
Abzena has the potential to earn future licence fees, milestone
payments and/or royalties on 'ABZENA Inside' products.
Abzena offers the following services and technologies across its
principal sites in Cambridge (UK), San Diego, California (USA) and
Bristol, Pennsylvania (USA):
-- Immunology research studies, including immunogenicity
assessment of candidate biopharmaceutical products;
-- Protein engineering to create humanized antibodies and deimmunised therapeutic proteins;
-- Cell line development for the manufacture of recombinant proteins and antibodies;
-- Contract process development and GMP manufacture of
biopharmaceuticals, including monoclonal antibodies and recombinant
proteins for preclinical and clinical studies;
-- Contract synthetic chemistry and bioconjugation research
services, focused on antibody-drug conjugates (ADCs);
-- Proprietary site-specific conjugation technologies and novel payloads for ADC development; and
-- GMP manufacturer of ADC linkers, payloads & combined linker-payloads.
For more information, please see www.abzena.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAEAAFLEEXPEAF
(END) Dow Jones Newswires
January 05, 2018 02:00 ET (07:00 GMT)
Abzena (LSE:ABZA)
Historical Stock Chart
From Apr 2024 to May 2024
Abzena (LSE:ABZA)
Historical Stock Chart
From May 2023 to May 2024